Background Magnesium sulphate is a common therapy in perinatal care. Its benefits when
given to women at risk of preterm birth for fetal neuroprotection (prevention of cerebral palsy …

Background Magnesium sulphate is extensively used in obstetrics for the treatment and
prevention of eclampsia. A recent meta‐analysis has shown that magnesium sulphate is an …

Background The effectiveness of antenatal magnesium sulphate for neuroprotection of the
fetus, infant, and child prior to very preterm birth, when given to women considered at risk of …

Background Epidemiological and basic science evidence suggests that magnesium
sulphate before birth may be neuroprotective for the fetus. Objectives To assess the effects …

Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate
for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …

Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …

Background Babies born preterm are at an increased risk of dying in the first weeks of life,
and those who survive have a higher rate of cerebral palsy (CP) compared with babies born …

Antenatal administration of magnesium sulfate is an important part of the neuroprotective
strategy for preterm infants. Strong evidence from five randomized controlled trials and five …

Antenatal magnesium sulphate reduces the risk of cerebral palsy in babies born< 30 weeks'
gestation. A guideline for its use in women at imminent risk of preterm birth was …